Michael R. Megna - Feb 28, 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF ACCOUNTING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Feb 28, 2024
Transactions value $
-$160,859
Form type
4
Date filed
3/1/2024, 06:26 PM
Previous filing
Jan 4, 2024
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Award $7.2K +583 +3.43% $12.35 17.6K Jan 15, 2024 Direct F1
transaction KNSA Class A Common Share Options Exercise $45.3K +5.13K +29.14% $8.83 22.7K Feb 28, 2024 Direct F2
transaction KNSA Class A Common Share Sale -$112K -5.13K -22.57% $21.79 17.6K Feb 28, 2024 Direct F2, F3
transaction KNSA Class A Common Share Options Exercise $49.8K +5.65K +32.1% $8.83 23.2K Mar 1, 2024 Direct F2
transaction KNSA Class A Common Share Options Exercise $55.7K +4.01K +17.28% $13.88 27.2K Mar 1, 2024 Direct F2
transaction KNSA Class A Common Share Sale -$207K -9.66K -35.45% $21.45 17.6K Mar 1, 2024 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -5.13K -46.6% $0.00 5.87K Feb 28, 2024 Class A Common Share 5.13K $8.83 Direct F2, F5
transaction KNSA Share Option Options Exercise $0 -5.65K -96.1% $0.00 229 Mar 1, 2024 Class A Common Share 5.65K $8.83 Direct F2, F5
transaction KNSA Share Option Options Exercise $0 -4.01K -100% $0.00* 0 Mar 1, 2024 Class A Common Share 4.01K $13.88 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2023 to January 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F2 This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.56 to $21.90. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.45 to $21.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5 This option is fully vested and exercisable.